Skip to main content

Table 1 Pre-treatment, treatment, and pathologic characteristics stratified by patient group

From: Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy

 

Group 1 (PSADT >3 months, DM absent at start of SADT) (n = 62)

Group 2 (PSADT <3 months, DM absent at start of SADT) (n = 28)

Group 3 (DM present at start of SADT) (n = 32)

Group 4 (No SADT) (n = 50)

 

Age at SRT (y), median (IQR)

65.7 (58.9–70.4)

63.0 (56.6–67.3)

63.6 (57.8–67.6)

62.3 (55.9–67.5)

p = 0.38*

CCMI, median (range) (n = 147)

3.0 (1.0–6.0)

3.0 (1.0–6.0)

3.0 (1.0–5.0)

3.0 (1.0–5.0)

p = 0.49*

Pre-SRT PSA (ng/mL), median (IQR) (n = 163)

0.9 (0.5–1.7)

1.0 (0.5–1.5)

0.6 (0.3–1.0)

0.5 (0.4–0.7)

p = 0.09*

SRT dose (Gy), median (IQR) (n = 171)

68.4 (64.8–68.4)

65.8 (64.8–68.4)

68.4 (64.8–68.4)

64.9 (64.8–68.4)

p = 0.22*

WPRT

11.3%

3.6%

12.5%

8.0%

p = 0.60**

ADT during SRT

12.9%

25.0%

12.5%

12.0%

p = 0.40**

Duration of ADT during SRT (mo), median (IQR)

6.4 (6.0–19.6)

6.2 (3.6–11.1)

6.0 (3.6–7.8)

6.0 (3.0–12.0)

p = 0.43*

Gleason score (n = 171)

     

2–6

9.8%

7.1%

3.1%

22.0%

p = 0.04**

7

63.9%

42.9%

53.1%

54.0%

p = 0.30**

8–10

26.2%

50.0%

43.8%

24.0%

p = 0.04**

pT stage (n = 146)

     

T1-T2a

10.4%

0.0%

3.3%

4.7%

p = 0.26**

T2b-T2c

18.8%

12.0%

16.7%

16.3%

p = 0.91**

T3-T4

70.8%

88.0%

80.0%

79.1%

p = 0.39**

SVI (n = 171)

21.0%

35.7%

34.4%

26.5%

p = 0.38**

ECE

54.8%

78.6%

75.0%

70.0%

p = 0.07**

SM (n = 169)

38.7%

53.6%

53.3%

36.7%

p = 0.28**

Undetectable PSA nadir post-SRT (n = 170)

69.4%

64.3%

81.30%

45.8%

p = 0.008**

PSA before SADT (ng/mL), median (IQR)

4.3 (2.0–6.7)

2.7 (1.0–8.0)

5.2 (2.4–9.7)

---

p = 0.21*

PSADT after SRT (mo), median (IQR)

6.0 (4.5–9.5)

2.2 (1.5–2.7)

4.1 (1.9–7.3)

27.0 (13.6–47.7)

p < 0.001*

IBF (mo), median (mean)

12.9 (18.1)

11.5 (18.5)

13.6 (13.8)

48.3 (48.7)

p < 0.001*

IBF <18 months

61.3%

67.9%

75.0%

12.0%

p < 0.0001**

  1. Abbreviations: PSADT = prostate-specific antigen doubling time, SADT = salvage androgen deprivation therapy, DM = distant metastasis, SRT = salvage radiation therapy, IQR = interquartile range, CCMI = Charlson Comorbidity Index, PSA = prostate-specific antigen, WPRT = whole-pelvic radiation therapy, ADT = androgen deprivation therapy, pT stage = pathologic T stage, SVI = seminal vesicle invasion, ECE = extracapsular extension, SM = presence of any positive surgical margin, IBF = interval to biochemical failure, *Analysis of variance, **Chi-square.